China Next-Generation Sequencing (NGS) Services Market (2017-2022)
The China Next-Generation Sequencing (NGS) Services Market was valued at $105 Million in 2017 and projected to reach to $295.3 Million by 2022, representing a compound annual growth rate of CAGR 23.0%. China's NGS services market is positioned for sustained growth through 2022 and beyond, supported by continued government investment in genomic infrastructure, expanding clinical applications, and increasing adoption among hospitals and diagnostic laboratories.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Next-Generation Sequencing (NGS) Services Market Trends and Insights
- In 2017, China's NGS services market was valued at $105.0 million, driven by increasing government investment in genomic research infrastructure and rising demand for cost-effective sequencing solutions.
- By 2022, China's market is forecast to reach $295.3 million, representing a compound annual growth rate (CAGR) of 23.0%, significantly outpacing global growth trends. The rapid expansion of China's NGS services sector is underpinned by several factors unique to the region.
- China's substantial population base, coupled with growing healthcare expenditure and government initiatives promoting precision medicine, has created favorable conditions for NGS service providers.
- China's competitive advantage in manufacturing and service delivery has enabled local providers to offer cost-competitive sequencing services, attracting both domestic and international clients.
- Additionally, China's investments in genomic databases and bioinformatics capabilities have strengthened the country's position as a leading NGS services hub in the Asia-Pacific region..
Key Market Statistics
- CAGR (2017-2022) CAGR 23.0%
- Market Size, 2017 ~USD 105 Million
- Forecast, 2022 ~USD 295.3 Million
- Country China
China Next-Generation Sequencing (NGS) Services Market Overview
Rapid Market Expansion :
China's NGS services market grew from $105.0 million in 2017 to $295.3 million in 2022, representing a 23% CAGR and outpacing the global growth rate of 21%, demonstrating strong domestic demand acceleration.
Government-Backed Infrastructure Investment :
Significant government funding for genomic research infrastructure and precision medicine initiatives has catalyzed NGS adoption across clinical diagnostics, research institutions, and healthcare facilities throughout China.
Clinical Diagnostics Leadership :
China's NGS services are increasingly integrated into clinical diagnostics for cancer genomics, rare disease identification, and prenatal screening, driven by rising healthcare spending and patient awareness of precision medicine benefits.
Emerging Precision Medicine Ecosystem :
The convergence of genomic research capabilities, pharmaceutical development, and personalized treatment protocols is establishing China as a key hub for NGS-driven precision medicine applications in Asia.
China Next-Generation Sequencing (NGS) Services Market Dynamics
- The market benefits from China's large patient population, rising healthcare expenditure, and strategic focus on precision medicine as a healthcare priority.
- Regulatory frameworks supporting genomic testing and growing collaboration between research institutions and commercial providers will further accelerate market penetration across tier-1 and tier-2 cities..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- China's NGS services market is projected to grow from $105.0 million in 2017 to $295.3 million in 2022, representing a 23.0% CAGR.
- China's government-backed genomic research initiatives and precision medicine programs are primary catalysts driving market expansion.
- China's cost-competitive service delivery model positions the country as a preferred NGS services destination for global clients.
- China's expanding bioinformatics infrastructure and genomic databases strengthen competitive positioning within the Asia-Pacific region.
Next-Generation Sequencing (NGS) Services Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2017 |
| Fastest Growing Segment | AGRICULTURE & ANIMAL RESEARCH (Application) |
| Forecast Period | 2017–2022 |
| Growth Rate | CAGR of 21% from 2017 to 2022 |
| Largest Segment | DIAGNOSTICS (Application) |
| Market Size Base Year (Billions) | ~USD 1.06 (2017) |
| Revenue Forecast (Billions) | ~USD 2.748 (2022) |
| Segments Covered | Type, Application, End User, Technology |
China Next-Generation Sequencing (NGS) Services Market Report Segmentation
4 segment dimensions are covered across the global market.
By Type
- Chip-Seq
- De Novo Sequencing
- Exome Sequencing
- Methyl-Seq
- Other Ngs Services
- Other Services
- Rna-Seq
- Targeted Sequencing/Custom Gene Panels
- Targeted Sequencing/Gene Panels
- Whole-Genome Sequencing
By Application
- Agriculture & Animal Research
- Biomarker Discovery
- Diagnostics
- Drug Discovery
- Infectious Diseases
- Oncology
- Other Applications
- Other Applications*
- Other Diagnostic Applications
- Rare Genetic Disorders
- Reproductive Health
By End User
- Academic & Government
- Academic & Government Institutes And Research Centers
- Hospitals & Clinics
- Other End Users
- Other End Users*
- Pharmaceutical & Biotechnology Companies
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Sequencing By Synthesis
- Single-Molecule Real-Time Sequencing
Target Audience
- NGS Service Providers & Diagnostics Companies : Require market sizing, growth projections, and competitive analysis to develop China-specific business strategies, pricing models, and service expansion plans in this rapidly growing genomic diagnostics market.
- Healthcare Investment & Private Equity Firms : Need validated market data, growth trajectories, and investment opportunities to evaluate acquisition targets, portfolio companies, and funding decisions in China's precision medicine and genomics sector.
- Pharmaceutical & Biotech Companies : Seek NGS market intelligence to understand companion diagnostic opportunities, precision medicine adoption rates, and clinical integration pathways for drug development and personalized treatment strategies in China.
- Hospital Networks & Healthcare Institutions : Require market analysis to assess NGS service adoption trends, clinical utility data, and infrastructure investment requirements for implementing genomic diagnostics and precision medicine programs.
- Government & Policy Makers : Need comprehensive market insights to inform healthcare policy, genomic research funding allocation, regulatory framework development, and precision medicine initiatives aligned with China's healthcare modernization goals.
Key Companies in the China Next-Generation Sequencing (NGS) Services Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ILLUMINA, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| PERKINELMER, INC. | United States | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| EUROFINS SCIENTIFIC SE | Luxembourg | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| MACROGEN, INC. | South Korea | Public Company | Targeted sequencing services,RNA-Seq services,Exome sequencing services, |
| QIAGEN N.V. | Netherlands | Public Company | Targeted sequencing services (panels, amplicon, gene panels),RNA-Seq services,Exome and de novo sequencing services, |
| DNA LINK, INC. | South Korea | Public Company | Whole genome & De Novo sequencing services,Whole exome & targeted sequencing services,Transcriptome & single-cell RNA sequencing, |
| TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.) | Japan | ||
| NOVOGENE CORPORATION | China | Public Company | Whole genome and targeted sequencing services (incl. human/animal/plant/microbial WGS and targeted panels),Transcriptomics and single-cell sequencing (mRNA, lncRNA, small RNA, single-cell, spatial),De novo, metagenomics, and microbiome sequencing, |
| PERSONALIS, INC. | United States | Public Company | Oncology MRD and monitoring (NeXT Personal, NeXT Personal Dx),Comprehensive tumor profiling (ImmunoID NeXT, NeXT Dx),Population and research sequencing (WES/WGS services), |
ILLUMINA, INC.
Illumina, Inc. is a public company founded in 1998 and headquartered in the United States with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies.
PERKINELMER, INC.
PerkinElmer, Inc. is a public company founded in 1937 and based in the United States with 11,000 employees. The company provides diagnostic and research solutions across life sciences and environmental testing.
EUROFINS SCIENTIFIC SE
Eurofins Scientific SE is a public company founded in 1987 and headquartered in Luxembourg with 65,694 employees. The company operates a network of laboratories providing testing and analytical services across multiple industries.
MACROGEN, INC.
Macrogen, Inc. is a public company founded in 2000 and based in South Korea with 293 employees. The company provides genomic research services including DNA sequencing and analysis.
QIAGEN N.V.
QIAGEN N.V. is a public company founded in 1984 and headquartered in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences tools.
DNA LINK, INC.
DNA Link, Inc. is a public company founded in 2000 and based in South Korea with 84 employees. The company offers genomic analysis and genetic testing services.
TAKARA BIO INC. (PART OF TAKARA HOLDING COMPANY INC.)
Takara Bio Inc. is a company based in Japan and operates as part of Takara Holding Company Inc. The company specializes in biotechnology and life sciences research products.
NOVOGENE CORPORATION
Novogene Corporation is a public company founded in 2011 and based in China with 2,225 employees. The company provides genomic sequencing and bioinformatics analysis services.
PERSONALIS, INC.
Personalis, Inc. is a public company founded in 2011 and based in the United States with 260 employees. The company develops genomic testing and analysis solutions for precision medicine.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China's NGS services sector with verified 23% CAGR, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
- Competitive Landscape Intelligence : Understand China-specific market dynamics, key players, service offerings, and competitive positioning to identify partnership opportunities and differentiation strategies in this high-growth genomic services market.
- Clinical Application Insights : Access detailed analysis of NGS adoption across cancer diagnostics, rare disease screening, and prenatal testing in China, revealing high-value clinical segments and unmet diagnostic needs.
- Regulatory & Infrastructure Assessment : Gain comprehensive understanding of China's genomic research infrastructure, government policies, reimbursement frameworks, and regulatory requirements affecting NGS service delivery and market accessibility.
- Strategic Growth Opportunities : Identify emerging opportunities in precision medicine, hospital partnerships, research collaborations, and geographic expansion across Chinese healthcare systems to maximize market penetration and revenue potential.
Frequently asked questions
What was China's NGS services market size in 2017?
China's NGS services market was valued at $105.0 million in 2017, establishing the baseline for subsequent growth projections.
What is the forecast size of China's NGS services market in 2022?
China's NGS services market is forecast to reach $295.3 million by 2022, reflecting strong market expansion over the five-year period.
What is the CAGR for China's NGS services market?
China's NGS services market is expected to grow at a compound annual growth rate (CAGR) of 23.0% from 2017 to 2022.
What factors are driving growth in China's NGS services market?
Key growth drivers in China include government investment in genomic research, rising precision medicine adoption, cost-competitive service delivery, and expanding bioinformatics capabilities.
How does China's NGS market growth compare to global trends?
China's 23.0% CAGR significantly exceeds the global NGS services market CAGR of 21%, demonstrating China's accelerated market expansion relative to worldwide trends.
RESEARCH METHODOLOGY
Get the Full Next-Generation Sequencing (NGS) Services Market Report
Full forecast, segment splits, and company analysis for all Next-Generation Sequencing (NGS) Services Market.
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
